A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2023.2188194
Abstract: ABSTRACT Background This study compares first-line toripalimab with chemotherapy for advanced nonsquamous non-small cell lung cancer (NSCLC) from the perspective of the Chinese healthcare system. Research design and methods A three-state Markov model was established… read more here.
Keywords: advanced nonsquamous; toripalimab; line toripalimab; first line ... See more keywords